Form 4: Amneal Pharmaceuticals Director Ted C. Nark Acquires Restricted Stock Units

Director Ted C. Nark acquired 40,258 restricted stock units of Amneal Pharmaceuticals, Inc. on May 2, 2024.

Summary

• On May 2, 2024, Ted C. Nark, a director of Amneal Pharmaceuticals, Inc., acquired 40,258 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Amneal's Class A Common Stock.
• The RSUs vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Mr. Nark directly owns 40,258 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units being granted, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, specifically the company's annual meeting and the anniversary of the grant date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a grant of restricted stock units, a common form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of restricted stock units by a director could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates